New Targets for Treating Cancer: Copper Death and Copper Accumulation in Cancer Cells

Hongxia Li; Xue Gao; Shaofeng Zhao; He Tian; Qinfang Wei

doi:10.54097/9v67nn75

Authors

Hongxia Li
Xue Gao
Shaofeng Zhao
He Tian
Qinfang Wei

DOI:

https://doi.org/10.54097/9v67nn75

Keywords:

Copper Death, Tumor Cells, Mitochondrial Lipoylation

Abstract

The accumulation of copper ions plays an important role in the apoptosis of cancer cells. Definition of copper death: Copper death (Cuproptosis) is a new form of programmed cell death caused by excessive copper. Copper ions can participate in multiple cellular signaling pathways and promote the growth and division of cancer cells. Copper ions are involved in angiogenesis, providing nutrients and oxygen for cancer cells and supporting the growth and spread of tumors. Together, they promote the progression of cellular inflammation. Copper ions are related to tumor metastasis and play a certain role in the migration and invasion of cancer cells.

Downloads

Download data is not yet available.

References

[1] LOPEZ J, RAMCHANDANI D, VAHDAT L. Copper Depletion as a Therapeutic Strategy in Cancer [J]. Metal ions in life sciences, 2019, 19.

[2] Tsvetkov P, Coy S, Petrova B, Dreishpoon M, Verma A, Abdusamad M, Rossen J, Joesch-Cohen L, Humeidi R, Spangler R D, Eaton J K, Frenkel E, Kocak M, Corsello S M, Lutsenko S, Kanarek N, Santagata S, Golub T R. Copper induces cell death by targeting lipoylated TCA cycle proteins[J]. Science (New York, NY), 2022, 375(6586):1254-1261.

[3] Hino K, Yanatori I, Hara Y, Nishina S. Iron and liver cancer: an inseparable connection[J]. FEBS J, 2022, 289(24):7810-7829.

[4] Tsvetkov P, Coy S, Petrova B, et al. Cuproptosis induces cell death by targeting lipoylated TCA cycle proteins[J]. Science, 2022, 375(6586): 1254-1261.

[5] WICHERSKA-PAWLOWSKA K, WROBEL T, RYBKA J. Tolllike receptors(TLRs),NOD-Like receptors(NLRs),and RIG-Ilike receptors(RLRs) in innate immunity. TLRs,NLRs,and RLRs ligands as immunotherapeutic agents for hematopoietic diseases[J]. Int J Mol Sci,2021,22(24): 13397.

[6] Cobine P A, Moore S A, Leary S C. Getting out what you put in: Cuproptosis in mitochondria and its impacts on human disease[J]. Biochimica Et Biophysica Acta (BBA)-Molecular Cell Research, 2021, 1868(1): 118867.

[7] Qian Y, Shi L, Luo Z. Long non-coding RNAs in cancer: implications for diagnosis, prognosis, and therapy[J]. Frontiers in medicine, 2020: 902.

[8] Y. Xue, H. Liu, G. Nie, and X. Ren, “lncRNA DARS-AS1 promoted osteosarcoma progression through regulating miR-532- 3p/CCR7,” Disease Markers, vol. 2022, Article ID 4660217, 9 pages, 2022.

[9] MAO C, YUAN J Q, YANG Z Y, et al. Blood as a Substitute for Tumor Tissue in Detecting EGFR Mutations for Guiding EGFR TKIs Treatment of Nonsmall Cell Lung Cancer: A Systematic Review and Meta-Analysis [J]. Medicine, 2015, 94(21): e775.

[10] OTSUBO K, SAKAI K, TAKESHITA M, et al. Genetic Profiling of Non-Small Cell Lung Cancer at Development of Resistance to First- or Second-Generation EGFR-TKIs by CAPP-Seq Analysis of Circulating Tumor DNA [J]. The oncologist, 2019, 24(8): 1022-6.

[11] ZHANG Y, XIONG L, XIE F, et al. Next-generation sequencing of tissue and circulating tumor DNA: Resistance mechanisms to EGFR targeted therapy in a cohort of patients with advanced non-small cell lung cancer [J]. Cancer medicine, 2021, 10(14): 4697-709.

[12] GARZA N M, SWAMINATHAN A B, MAREMANDA K P, et al. Mitochondrial copper in human genetic disorders [J]. Trends in endocrinology and metabolism: TEM, 2023, 34(1): 21-33.

[13] CHEN X, CAI Q, LIANG R, et al. Copper homeostasis and copper-induced cell death in the pathogenesis of cardiovascular disease and therapeutic strategies [J]. Cell death & disease, 2023, 14(2): 105.

[14] AN Y, LI S, HUANG X, et al. The Role of Copper Homeostasis in Brain Disease [J]. International journal of molecular sciences, 2022, 23(22).

[15] JU Y S. A large-scale snapshot of intratumor heterogeneity in human cancer [J]. Cancer cell, 2021, 39(4): 463-5.

[16] KOLLáROVIČ G, TOPPING C E, SHAW E P, et al. The human HELLS chromatin remodelling protein promotes end resection to facilitate homologous recombination and contributes to DSB repair within heterochromatin [J]. Nucleic acids research, 2020, 48(4): 1872-85.

[17] NI K, MUEGGE K. LSH catalyzes ATP-driven exchange of histone variants macroH2A1 and macroH2A2 [J]. Nucleic acids research, 2021, 49(14): 8024- 36.

[18] CHEN X, LI Y, RUBIO K, et al. Lymphoid-specific helicase in epigenetics, DNA repair and cancer [J]. British journal of cancer, 2022, 126(2): 165-73.

[19] XU X, NI K, HE Y, et al. The epigenetic regulator LSH maintains fork protection and genomic stability via MacroH2A deposition and RAD51 filament formation [J]. Nature communications, 2021, 12(1): 3520.

[20] SONG Y,GAO N,YANG Z,et al. COX7B is a new prognostic biomarker and correlates with tumor immunity in esophageal carcinoma[J]. Mediators Inflamm,2023,2023: 6831695.

[21] Huang H, Zhang S, Li Y, et al. Suppression of mitochondrial ROS by prohibitin drives glioblastoma progression and therapeutic resistance[J]. Nature communications, 2021, 12(1): 1-16.

[22] C. Wang, T. Zhang, L. Yang, X. Na, and Y. Qu, “lncRNA BACE1-AS promotes the progression of osteosarcoma through miR-762/SOX7 axis,” Molecular Biology Reports, vol. 49, no. 7, pp. 5853–5862, 2022.

[23] Q. Liu, J. Luo, H. Wang, L. Zhang, and G. Jin, “SNHG1 functions as an oncogenic lncRNA and promotes osteosarcoma progression by up-regulating S100A6 via miR-493-5p,” Acta Biochim Biophys Sin (Shanghai), vol. 54, no. 1, pp. 137–147,

[24] W. Guo, X. Zhang, L. Lin et al., “The disulfifiram/copper complex induces apoptosis and inhibits tumour growth in human osteosarcoma by activating the ROS/JNK signalling pathway,” Journal of Biochemistry, vol. 170, no. 2, pp. 275–287, 2021.

[25] CHEN L, MIN J, WANG F. Copper homeostasis and cuproptosis in health and disease [J]. Signal transduction and targeted therapy, 2022, 7(1): 378.

[26] GE E J, BUSH A I, CASINI A, et al. Connecting copper and cancer: from transition metal signalling to metalloplasia [J]. Nature reviews Cancer, 2022, 22(2): 102-13.

[27] XIE J, YANG Y, GAO Y, et al. Cuproptosis: mechanisms and links with cancers [J]. Molecular cancer, 2023, 22(1): 46.

[28] DA SILVA D A, DE LUCA A, SQUITTI R, et al. Copper in tumors and the use of copper-based compounds in cancer treatment [J]. Journal of inorganic biochemistry, 2022, 226: 111634.

[29] Li G, Liu K, Du X. Long non-coding RNA TUG1 promotes prolifer⁃ ation and inhibits apoptosis of osteosarcoma cells by sponging miR-132-3p and upregulating SOX4 expression [J]. Yonsei Med J, 2018, 59 (2): 226-235.

[30] KRISHNAN N, FELICE C, RIVERA K, et al. DPM-1001 decreased copper levels and ameliorated deficits in a mouse model of Wilson's disease [J]. Genes & development, 2018, 32(13-14): 944-52.

[31] BRADY D C, CROWE M S, GREENBERG D N, et al. Copper Chelation Inhibits BRAF(V600E)-Driven Melanomagenesis and Counters Resistance to BRAF(V600E) and MEK1/2 Inhibitors [J]. Cancer research, 2017, 77(22): 6240-52.

[32] Zhang Z, Hao R, Guo Q, et al. TP53 mutation infers a poor prognosis and is correlated to immunocytes infiltration in breast cancer[J]. Front Cell Dev Biol, 2021, 9: 759154.

[33] LAI S, CHEN Y, YANG F, et al. Quantitative Site-Specific Chemoproteomic Profiling of Protein Lipoylation [J]. Journal of the American Chemical Society, 2022, 144(23): 10320-9.

[34] ROWLAND E A, SNOWDEN C K, CRISTEA I M. Protein lipoylation: an evolutionarily conserved metabolic regulator of health and disease [J]. Current opinion in chemical biology, 2018, 42: 76-85.

[35] Liu S, Wang Z, Zhu R, et al. Three Differential Expression Analysis Methods for RNA Sequencing: limma, EdgeR, DESeq2[J]. Journal of visualized experiments: JoVE, 2021 (175).

[36] Hu K. Become competent in generating RNA-seq heat maps in one day for novices without prior R experience[M]//Nuclear Reprogramming. Humana, New York, NY, 2021: 269-303.

[37] Bai H, Liu H, Lu J. Development of a four-mRNA expression-based prognostic signature for cutaneous melanoma[J]. Frontiers in Genetics, 2021, 12: 966.

[38] Cao R, López-de-Ullibarri I. ROC curves for the statistical analysis of microarray data[J]. Microarray Bioinformatics, 2019: 245-253.

[39] ]Rossi K R, Echeverria D, Carroll A, et al. Development and evaluation of Perl-based algorithms to classify neoplasms from pathology records in synoptic report format[J]. JCO Clinical Cancer Informatics, 2021, 5: 295-303.

[40] ORSOLIC I, CARRIER A, ESTELLER M. Genetic and epigenetic defects of the RNA modification machinery in cancer [J]. Trends in genetics : TIG, 2023, 39(1): 74-88.

[41] BAYLIN S B, JONES P A. Epigenetic Determinants of Cancer [J]. Cold Spring Harbor perspectives in biology, 2016, 8(9).

[42] DAWSON M A. The cancer epigenome: Concepts, challenges, and therapeutic opportunities [J]. Science (New York, NY), 2017, 355(6330): 1147-52.

[43] YANG R, LIU N, CHEN L, et al. GIAT4RA functions as a tumor suppressor in non-small cell lung cancer by counteracting Uchl3-mediated deubiquitination of LSH [J]. Oncogene, 2019, 38(46): 7133-45.

[44] GE E J, BUSH A I, CASINI A, et al. Connecting copper and cancer: from transition metal signalling to metalloplasia [J]. Nature reviews Cancer, 2022, 22(2): 102-13.

[45] XIE J, YANG Y, GAO Y, et al. Cuproptosis: mechanisms and links with cancers [J]. Molecular cancer, 2023, 22(1): 46.

[46] VIOLA-RHENALS M, PATEL K R, JAIMES-SANTAMARIA L, et al. Recent Advances in Antabuse (Disulfiram): The Importance of its Metal-binding Ability to its Anticancer Activity [J]. Current medicinal chemistry, 2018, 25(4): 506-24.

[47] HE X, YAN B, LIU S, et al. Chromatin Remodeling Factor LSH Drives Cancer Progression by Suppressing the Activity of Fumarate Hydratase [J]. Cancer research, 2016, 76(19): 5743-55.

[48] Mo X, Hu D, Yang P, et al. A novel cuproptosis-related prognostic lncRNAs signature and lncRNAs MIR31HG/miR- 193a-3p/TNFRSF21 regulatory axis in lung adenocarcinoma [J]. Front Oncol, 2022, 12: 927706.

[49] Ueno T, Kitano S, Masuda N, et al. Immune microenvironment, homologous recombination deficiency, and therapeutic response to neoadjuvant chemotherapy in triple-negative breast cancer: Japan Breast Cancer Research Group (JBCRG) 22 TR[J]. BMC medicine, 2022, 20(1): 1-10.

[50] Ueno T, Kitano S, Masuda N, et al. Immune microenvironment, homologous recombination deficiency, and therapeutic response to neoadjuvant chemotherapy in triple-negative breast cancer: Japan Breast Cancer Research Group (JBCRG) 22 TR[J]. BMC medicine, 2022, 20(1): 1-10.

[51] Wang Z, Guo X, Gao L, et al. Glioblastoma cell differentiation trajectory predicts the immunotherapy response and overall survival of patients[J]. Aging (Albany NY), 2020, 12(18): 18297.

[52] Chen X, Sun X, Li X, et al. LncRNA-HEIH is a novel diagnostic and predictive biomarker in gastric cancer[J]. Genetic Testing and Molecular Biomarkers, 2021, 25(4): 284-292.

[53] ALVAREZ M S, NUNEZ E, FUERTES-AGUDO M, et al. Quantitative proteomics analysis reveal that cyclooxygenase-2 modulates mitochondrial respiratory chain complex Ⅳ in cardiomyocytes[J]. Int J Mol Sci,2022,23(21): 13476.

[54] Chang M, Wang M, Wang M, et al. A multifunctional cascade bioreactor based on hollow-structured Cu2MoS4 for synergetic cancer chemo-dynamictherapy/ starvation therapy/ phototherapy/ immunotherapy with remarkably enhanced efficacy [J]. Advanced Materials, 2019, 31: 1905271.

[55] ZHANG P,YANG H,ZHU K,et al. SLC31A1 identifying a novel biomarker with potential prognostic and immunotherapeutic potential in pan-cancer[J]. Biomedicines, 2023, 11(11): 2884.

[56] J. Zhang, C. Huang, G. Zhu et al., “Selection of lncRNAs that inflfluence the prognosis of osteosarcoma based on copy number variation data,” Journal of Oncology, vol. 2022, Article ID 8024979, 21 pages, 2022.HUO S,WANG Q,SHI W,et al.

[57] ATF3/SPI1/SLC31A1 signaling promotes cuproptosis induced by advanced glycosylation and products in diabetic myocardial injury[J]. Int J Mol Sci,2023,24 (2): 1667.

[58] Siegel R L, Miller K D, Fuchs H E, et al. Cancer statistics, 2022 [J]. CA: a cancer journal for clinicians, 2022, 72: 7-33.

[59] Zhao Q S, Ying J B, Jing J J, et al. LncRNA FOXD2-AS1 stimulates glioma progression through inhibiting P53[J]. Eur Rev Med Pharmacol Sci, 2020, 24(8): 4382- 8.